Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML

NCT02229266 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped low recruitment rate

Conditions

Acute Myeloid Leukemia

Interventions

BIOLOGICAL: NK cells
DRUG: Cytarabine

Sponsor

Technische Universität Dresden

Collaborators

[object Object]